Faculty, Staff and Student Publications
Publication Date
2-8-2023
Journal
The Oncologist
DOI
10.1093/oncolo/oyac254
PMID
36576431
PMCID
PMC9907041
PubMedCentral® Posted Date
12-28-2022
PubMedCentral® Full Text Version
Post-print
Abstract
Colorectal cancer (CRC) is a heterogeneous and complex disease with limited treatment options. Targeting transforming growth factor β (TGF-β) and programmed death ligand 1 pathways may enhance antitumor efficacy. Bintrafusp alfa is a first-in-class bifunctional fusion protein composed of the extracellular domain of TGF-β receptor II (a TGF-β "trap") fused to a human IgG1 monoclonal antibody blocking programmed cell death ligand 1. We report results from an expansion cohort of a phase I study (NCT02517398) in patients with heavily pretreated advanced CRC treated with bintrafusp alfa. As of May 15, 2020, 32 patients with advanced CRC had received bintrafusp alfa for a median duration of 7.1 weeks. The objective response rate was 3.1% and the disease control rate was 6.3% (1 partial response, 1 stable disease); 2 patients were not evaluable. The safety profile was consistent with previously reported data.
Keywords
Humans, B7-H1 Antigen, Transforming Growth Factor beta, Antibodies, Monoclonal, Immunologic Factors, Colorectal Neoplasms, colorectal cancer, bintrafusp alfa, phase I
Published Open-Access
yes
Recommended Citation
Spira, Alexander; Wertheim, Michael S; Kim, Edward J; et al., "Bintrafusp Alfa: A Bifunctional Fusion Protein Targeting PD-L1 and TGF-β, in Patients with Pretreated Colorectal Cancer: Results from a Phase I Trial" (2023). Faculty, Staff and Student Publications. 4583.
https://digitalcommons.library.tmc.edu/uthgsbs_docs/4583
Included in
Bioinformatics Commons, Biomedical Informatics Commons, Genetic Phenomena Commons, Medical Genetics Commons, Oncology Commons